SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient

BMJ Case Rep. 2022 Sep 16;15(9):e250233. doi: 10.1136/bcr-2022-250233.

Abstract

Euglycaemic diabetic ketoacidosis is a serious but rare adverse effect of treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. A man in his 60s with type 2 diabetes mellitus underwent total hip replacement for an intracapsular neck of femur fracture. His SGLT-2 inhibitor was continued perioperatively and blood glucose levels were normal throughout the admission. A diagnosis of severe euglycaemic diabetic ketoacidosis was made in the operating theatre which required treatment in a critical care unit. This resulted in increased morbidity due to decreased postoperative mobilisation and a new requirement for subcutaneous insulin. This case highlights the need for withholding SGLT-2 inhibitors in patients admitted for emergency surgery and a need for regular ketone monitoring in these patients, even in the context of normoglycaemia.

Keywords: Diabetes; Orthopaedics; Perioperative care; Unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetic Ketoacidosis* / chemically induced
  • Diabetic Ketoacidosis* / diagnosis
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Insulin
  • Ketones / adverse effects
  • Male
  • Orthopedics*
  • Sodium
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Ketones
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium